gms | German Medical Science

27. Wissenschaftlicher Kongress der Deutschen Hochdruckliga

Deutsche Liga zur Bekämpfung des hohen Blutdrucks – Deutsche Hypertonie Gesellschaft e. V.

26. bis 29.11.2003, Bonn

The MARPLE-Project: Microalbuminuria as a risk predictor in hypertension. A long-term evaluation with ramipril - Final results

MARPLE-Projekt: Mikroalbuminurie als Risikoprädiktor bei Hypertonie - Langzeitbeobachtung mit Ramipril - Endergebnisse

Meeting Abstract (Hypertonie 2003)

  • presenting/speaker J. Schrader
  • S. Lüders
  • M. Dromowicz
  • A. Kulschewski
  • F. Hammersen
  • C. Züchner
  • U. Venneklaas
  • M. Schnieders
  • A. Gansz
  • G. Schrandt

Hypertonie 2003. 27. Wissenschaftlicher Kongress der Deutschen Hochdruckliga. Bonn, 26.-29.11.2003. Düsseldorf, Köln: German Medical Science; 2004. Doc03hochV24

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter:

Veröffentlicht: 11. November 2004

© 2004 Schrader et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.




Microalbuminuria (MAU) is a first sign for renal organ damage in hypertension. A consequent antihypertensive therapy may positively influence an existing MAU or even reverse it completely. Possible relationships to blood pressure and cardiovascular (cv) changes have been reported. In addition, a correlation between blood pressure and MAU is known for the ambulatory 24h blood pressure measurement (ABPM).


1. To determine the frequency of MAU.

2. Evaluation of an ACE-inhibitor (ramipril) therapy on blood pressure, the incidence or conversion of MAU and concomitant cv diseases in non-diabetic patients with hypertension.

3. Evaluation if normalization of MAU leads to decrease of cv events.


Prospective, controlled, open multi-centre project. Non-diabetic patients with hypertension without known renal diseases between 50 and 80 years not previously been treated with ramipril before were to be included when medical practitioner decided to start treatment with ramipril. ABPM and proteinuria-analysis was performed once a year up to 5 years. Determination of albumin-, total protein- and alpha1-microglobulin-excretion was carried out by quantitative protein measurement (nephelometry) in central laboratory of St.-Josefs-Hospital, Cloppenburg. Additionally SDS-electrophoresis was performed.


4654 patients had been screened. About 75% of them were documented in long-term follow up (mean 3.5 years). In 51.5%, no proteinuria was observed, 33% were showing MAU. Signs of tubular damage occurred in 12.1%, and 3.4% of all patients revealed selective- or unselective-glomerular proteinuria.

Final results will be presented concerning blood pressure, cardiovascular events and outcome comparing patients with and without MAU.